Radiopharm Theranostics Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Radiopharm Theranostics stock has a consensus rating of "Strong Buy" and an average price target of $16.86. The average 1-year stock price forecast is 302.39% higher than the current stock price, while the lowest is $12.53 (+199.05%) and the highest is $29.8 (+611.22%).

Price Target: $16.86 (+302.39%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$12.53	$16.86	$15.19	$29.8
Change	+199.05%	+302.39%	+262.53%	+611.22%

Analyst Ratings

The average analyst rating for Radiopharm Theranostics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	3	3	3	3	3	4
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Initiates $16	Buy	Initiates	$16	+281.86%	Jun 4, 2026
Michael Okunewitch Maxim Group	Maxim Group	Buy Maintains $15	Buy	Maintains	$15	+258.00%	Mar 26, 2026
Justin Walsh JonesTrading	JonesTrading	Buy Reiterates $30	Buy	Reiterates	$30	+615.99%	Mar 25, 2026

Financial Forecast

Revenue This Year

3.80M

from 12.51M

-69.59%

from 12.51M

Revenue Next Year

17.17M

from 3.80M

351.32%

from 3.80M

EPS This Year

-0.04

from -0.06

EPS Next Year

-0.03

from -0.04

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Jun 30, 2021	Jun 30, 2022	Jun 30, 2023	Jun 30, 2024	Jun 30, 2025	Jun 30, 2026
Revenue	-	-	6.21M	1.96M	12.51M	3.80M
Revenue Growth	-	-	-	-68.46%	538.86%	-69.59%
Gross Profit	-	-7.49M	-13.32M	-19.65M	-18.60M	83.70K
Gross Margin	-	-	-214.53%	-1,003.25%	-148.63%	2.20%
Operating Income	-1.16M	-19.93M	-28.59M	-35.33M	-35.13M	-173.73M
Net Income	-1.16M	-30.42M	-34.61M	-47.95M	-38.34M	-179.78M
EPS	-	-	-	-	-0.06	-0.04
Free Cash Flow	-	-31.35M	-12.08M	-12.04M	-23.62M	-147.59M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.

Revenue Forecast

Revenue	2026	2027	2028
High	10.5M
Avg	3.8M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	-16.5%
Avg	-69.6%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-0.03
Avg	-0.04
Low	-0.05

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-